Neurocrine Biosciences (NBIX) EV to CFO (2018 - 2026)
Neurocrine Biosciences' (NBIX) EV to CFO stood at 18.63 in Q2 2026, down 7.8% from 20.21 a year earlier but up 34.8% from the prior quarter.
Powered by 
Analysis
Neurocrine Biosciences (NBIX) EV to CFO (2018 - 2026) Analysis & Trends
On a TTM basis, Neurocrine Biosciences' EV to CFO came in at 14.28 as of Jun 30, 2026, down 1.5% year-over-year; for FY2025, it was 16.25, down 22.6% from FY2024.
- Annual EV to CFO has declined for three straight years.
- Across earlier years, EV to CFO came in at 20.98 in FY2024 (-31.6%), 30.69 in FY2023 (-1.1%), 31.02 in FY2022 (+8.0%) and 28.73 in FY2021 (-19.5%).
- Quarterly EV to CFO has ranged from 13.82 in Q1 2026 to 64.40 in Q1 2022 over the past five years.
- On a year-over-year basis, EV to CFO has declined for 14 consecutive quarters, with an average decline of 15.8% over the last eight quarters.
- Peak year-over-year performance for EV to CFO in the last five years was growth of 117.1% in Q1 2022, against a decline of 48.2% in Q3 2023 at the low end.
- Per Business Quant, the preceding three quarters came in at 13.82 (Q1 2026), 16.25 (Q4 2025) and 20.23 (Q3 2025).
Peer Set
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Johnson & Johnson | 645.01 Bn | 563.54 Bn | 17.26 Bn |
| 2 | AbbVie | 465.23 Bn | 438.39 Bn | 12.70 Bn |
| 3 | Merck | 368.40 Bn | 322.83 Bn | 12.21 Bn |
| 4 | Novartis Ag | 278.02 Bn | 233.89 Bn | 11.24 Bn |
| 5 | Astrazeneca | 254.57 Bn | 228.13 Bn | 12.86 Bn |
| 6 | Amgen | 229.02 Bn | 184.42 Bn | 7.24 Bn |
| 7 | Gilead Sciences | 187.74 Bn | 161.85 Bn | 6.22 Bn |
| 8 | Pfizer | 163.75 Bn | 110.70 Bn | 10.94 Bn |
| 9 | Vertex Pharmaceuticals | 133.45 Bn | 105.45 Bn | 2.84 Bn |
| 10 | Neurocrine Biosciences | 14.06 Bn | 9.76 Bn | 935.80 Mn |
Historic Data
Download Data
Historic Data
| Date | Value |
|---|---|
| Jun 30, 2026 | 18.63 |
| Mar 31, 2026 | 13.82 |
| Dec 31, 2025 | 16.25 |
| Sep 30, 2025 | 20.23 |
| Jun 30, 2025 | 20.21 |
| Mar 31, 2025 | 18.88 |
| Dec 31, 2024 | 20.98 |
| Sep 30, 2024 | 21.90 |
| Jun 30, 2024 | 24.23 |
| Mar 31, 2024 | 19.62 |
| Dec 31, 2023 | 30.69 |
| Sep 30, 2023 | 24.31 |
| Jun 30, 2023 | 27.78 |
| Mar 31, 2023 | 35.23 |
| Dec 31, 2022 | 31.02 |
| Sep 30, 2022 | 46.90 |
| Jun 30, 2022 | 53.00 |
| Mar 31, 2022 | 64.40 |
| Dec 31, 2021 | 28.73 |
| Sep 30, 2021 | 24.01 |
API Access
Neurocrine Biosciences EV to CFO API
Pull this series into your own models, spreadsheets and apps with the Business Quant
Historical Metrics API. The request below matches the chart above — change the
frequency, period or values and it follows. Swap YOUR_API_KEY for your own key.
https://data.businessquant.com/historic?slug=ev-to-cfo&ticker=NBIX&period=max&api_key=YOUR_API_KEYimport requests
url = "https://data.businessquant.com/historic"
params = {"slug": "ev-to-cfo", "ticker": "NBIX", "period": "max", "api_key": "YOUR_API_KEY"}
data = requests.get(url, params=params).json()const res = await fetch("https://data.businessquant.com/historic?slug=ev-to-cfo&ticker=NBIX&period=max&api_key=YOUR_API_KEY");
const data = await res.json();